SpinalMuscularAtrophy.net

Disease-Modifying Drugs for Spinal Muscular Atrophy

Reviewed by: HU Medical Review Board | Last reviewed: September 2026 | Last updated: November 2026

Spinal muscular atrophy (SMA) is a disease that makes muscles weak over time. It happens when the body cannot make enough of a protein called survival motor neuron (SMN) protein. This protein keeps the nerve cells that control movement healthy. These nerve cells are called motor neurons. Without enough SMN protein, motor neurons die and muscles grow weak.1

The US Food and Drug Administration (FDA) has approved several drugs to treat SMA. These are called disease-modifying drugs. They raise the amount of SMN protein in the body. This helps protect motor neurons and slow muscle loss.1

Starting treatment early makes a big difference. Babies who begin treatment before symptoms start have a better chance to live longer and reach movement milestones. Today, all 50 states screen newborns for SMA. This helps many babies get found and treated early.2

Talk to your child’s doctor to learn which drug may be right. The best choice depends on age, health, and the type of SMA.

How do disease-modifying drugs work?

Most people with SMA are missing part of a gene called SMN1. This gene normally tells the body how to make SMN protein. A backup gene, called SMN2, can make a small amount of the protein. People with more copies of SMN2 often have milder disease.1

By providing your email address, you are agreeing to our Privacy Notice and Terms of Use.

The approved drugs work in one of 2 ways:

  • Boost the backup gene – Some drugs help the SMN2 gene make more working SMN protein.
  • Replace the missing gene – Others add a new, working copy of the SMN1 gene through gene therapy.

Spinraza® (nusinersen)

The FDA approved Spinraza® in December 2016. It was the first drug approved for SMA. It treats infants, children, and adults.3,4

In 2026, the FDA approved a higher-dose option of Spinraza. It is meant to raise SMN protein levels even more, and it is approved for all people living with SMA.3,5

Spinraza is given as a shot into the fluid around the spinal cord. It helps the SMN2 gene make more SMN protein. Common side effects can include headache, back pain, vomiting, constipation, and cold-like symptoms.3,5

Zolgensma® (onasemnogene abeparvovec)

The FDA approved Zolgensma® in 2019 for children younger than 2 years. It is a gene therapy. It gives motor neurons a new, working copy of the SMN gene. A harmless virus carries the gene into the body. Zolgensma is given 1 time, through a vein.6

Zolgensma has a boxed warning, the strictest warning from the FDA. It has this warning because it can cause serious liver injury. Doctors check liver health for at least 3 months after treatment. The most common side effects are higher liver enzyme levels and vomiting.6

Itvisma® (onasemnogene abeparvovec)

In November 2025, the FDA approved Itvisma®. It uses the same gene therapy as Zolgensma, but Itvisma is approved for people 2 years and older with any type of SMA. It is given 1 time as a shot into the fluid around the spinal cord.7

Like Zolgensma, Itvisma can affect the liver, so doctors watch liver health closely. Common side effects can include fever, headache, dizziness, upper respiratory infections, and low platelet counts.7

Evrysdi® (risdiplam)

The FDA approved Evrysdi® in 2020. It was the first SMA drug taken by mouth. It helps the SMN2 gene make more SMN protein.8

At first, it was approved for people 2 months and older. In 2022, the FDA expanded it to include babies under 2 months. Now it is approved for children and adults of all ages.9

Common side effects can include fever, diarrhea, rash, mouth sores, joint pain, and urinary tract infections.8

IsembyldTM (apitegromab)

The FDA approved IsembyldTM in September of 2026 for adults and children 2 years of age and older who are currently receiving an SMN2-targeted treatment.10

Isembyld is the first approved SMA treatment that directly targets muscle loss, working in combination with other treatments to address a critical treatment need.10

Talk to your doctor

Side effects can vary depending on the drug you or your child is taking. These are not all the possible side effects of these drugs. Talk to your doctor about what to expect. Call your doctor if you have any changes that concern you.

Before starting treatment for SMA, tell your doctor about all your health conditions. Also share any other drugs, vitamins, or supplements you take. This includes over-the-counter drugs. These drugs are costly, so ask your care team about insurance and financial help. You are not alone – your care team can help you find the plan that is right for you.

Treatment results and side effects can vary from person to person. This treatment information is not meant to replace professional medical advice. Talk to your doctor about what to expect before starting and while taking any treatment.